Roche’s Alecensa Latest Beneficiary of Faster China Drug Approvals
ZURICH – Chinese regulators are speeding up drug approvals, with Roche’s Alecensa cancer medicine the latest beneficiary in a market that is growing increasingly important for international pharmaceuticals companies’ growth plans.
China’s National Drug Administration backed the Swiss drugmaker’s Alecensa to treat a kind of lung cancer, called anaplastic lymphoma kinase-, or ALK-positive, less than a year after European and U.S. approvals.
– Reuters
